Cramer's Mad Money - 8 Stocks that Measure the Market (11/3/09)

by: Miriam Metzinger

Stocks discussed on the in depth session of Jim Cramer's Mad Money TV Program, Tuesday November 3.

Burlington Northern Santa Fe (BNI), JP Morgan Chase (NYSE:JPM), Wells Fargo (NYSE:WFC), Goldman Sachs (NYSE:GS), Bank of America (NYSE:BAC), Google (NASDAQ:GOOG), Apple (NASDAQ:AAPL), Chevron (NYSE:CVX), Schlumberger (NYSE:SLB), Procter&Gamble (NYSE:PG), General Mills (NYSE:GIS), McDonald's (NYSE:MCD), WellPoint (WLP), Kimberly-Clark (NYSE:KMB), Bristol-Myers Squibb (NYSE:BMY)

Warren Buffett used to be a major mover of the market; but his purchase of Burlington Northern Santa Fe (BNI) on Tuesday didn't rock the Dow. Buffett isn't to be blamed, since he isn't all-powerful. Cramer says the only thing that can bring the market back up is strength in three sectors: banks, tech and oil. Eight stocks in these sectors which gauge the health of the economy are: JP Morgan Chase (JPM), Wells Fargo (WFC), Goldman Sachs (GS), Bank of America (BAC), Google (GOOG), Apple (AAPL), Chevron (CVX) and Schlumberger (SLB).

However, as long as the economy is slowing down, Cramer would buy defensive names instead: Procter&Gamble (PG), General Mills (GIS), McDonald's (MCD), WellPoint (WLP), Kimberly-Clark (KMB), Bristol-Myers Squibb (BMY).

If all three sectors are working on Friday, and if there is a strong jobs number, the Dow could see a 200-300 point rise. (NASDAQ:ACOM)

A dot-com IPO may sound like a throwback to the 90s, but (which will trade under the ticker ACOM) is actually profitable. The new IPO has been called "The Google of genealogy" and "Facebook for the over 65 crowd." Cramer thinks this subscription-based IPO could "pop on day one." While appeals to the more mature set, it has a loyal following, with subscriptions growing 11% and 38% at the premium level. The site combs through billions of historical documents to provide personal genealogical records for its clients. Currently, 0.6% of the over 45 population are subscribers, but the company aims to raise that figure to 5%.

Cramer is not thrilled that a private equity firm Spectrum Equity owns 67% of the company, but the IPO should bring this number down to 54%, and at least doesn't have the kind of debt that characterizes most IPOs with large private equity stakes. On Wednesday,'s IPO should be within the $12.50-$15.50 range, and Cramer thinks the stock is worth up to $18. He cautioned investors to buy the IPO and not the regular stock in the aftermarket.

Celgene (NASDAQ:CELG)'s Catalyst

Cramer likes Celgene, but would wait before buying; according to technical data, the stock should pull back from $50 to $48. His main reason for getting behind the stock is its successful drug Revlimid, which is the leading treatment for multiple myeloma, a cancer of the plasma cells in the bone marrow. Tests are showing that Revlimid can be used for other types of blood cancer. Celgene trades at 19 times 2010 earnings, but this is not so pricey taking into account the company's 24% growth rate. Cramer would wait to buy Celgene a week before the American Society of Hematology meeting on Dec. 5, where some "terrific Revlimid data" should be released.


Seeking Alpha publishes a summary of Jim Cramer's stock picks every day including: Mad Money Recap, Lightning Round and his Stop Trading! Picks.

Get Cramer's Picks by email-- it's free and takes only a few seconds to sign up.

Seeking Alpha is not affiliated with Jim Cramer, CNBC or